[1]钟 航,王 婷,张华文.扶阳清毒法联合HAIC治疗对中晚期肝癌患者肿瘤标志物水平及毒副反应的影响[J].医学信息,2025,38(24):118-122.[doi:10.3969/j.issn.1006-1959.2025.24.024]
　ZHONG Hang,WANG Ting,ZHANG Huawen.Effect of Fuyang Qingdu Method Combined with HAIC on Tumor Marker Levelsand Toxicity in Patients with Advanced Liver Cancer[J].Journal of Medical Information,2025,38(24):118-122.[doi:10.3969/j.issn.1006-1959.2025.24.024]
点击复制

扶阳清毒法联合HAIC治疗对中晚期肝癌患者肿瘤标志物水平及毒副反应的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年24期
页码:
118-122
栏目:
论著
出版日期:
2025-12-15

文章信息/Info

Title:
Effect of Fuyang Qingdu Method Combined with HAIC on Tumor Marker Levelsand Toxicity in Patients with Advanced Liver Cancer
文章编号:
1006-1959（2025）24-0118-05
作者:
钟 航; 王 婷; 张华文
赣州市南康区中医院肿瘤科，江西 赣州 34140
Author(s):
ZHONG Hang;  WANG Ting;  ZHANG Huawen
Department of Oncology, Nankang District Hospital of Traditional Chinese Medicine, Ganzhou 341400, Jiangxi, China
关键词:
扶阳清毒法; 肝动脉灌注化疗; 中晚期肝癌; 肿瘤标志物; 毒副反应
Keywords:
Fuyang Qingdu method;  Hepatic artery infusion chemotherapy;  Advanced liver cancer;  Tumor markers;  Toxicity
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2025.24.024
文献标志码:
A
摘要:
目的 探讨扶阳清毒法方药联合肝动脉灌注化疗（HAIC）治疗对中晚期肝癌患者肿瘤标志物水平及毒副反应的影响。方法 选取2024年5月-2025年5月赣州市南康区中医院收治的60例中晚期肝癌患者作为研究对象，按照随机数字表法将其分为对照组和治疗组，每组30例。对照组给予HAIC治疗，治疗组在对照组基础上给予扶阳清毒法方药治疗。比较两组临床疗效、中医证候积分（胁肋疼痛、腹胀、纳差、乏力）、肝功能[总胆红素（TBIL）、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、白蛋白（ALB）]、凝血功能[凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）]、甲胎蛋白（AFP）水平及毒副反应发生率（恶心呕吐、骨髓抑制、肝功能损害、肾功能损害）。结果 治疗组总有效率为83.33%，高于对照组的66.67%（P＜0.05）。治疗后，两组胁肋疼痛、腹胀、纳差、乏力中医证候积分均降低（P＜0.05），且治疗组低于对照组（P＜0.05）。两组AST、ALT、TBIL、AFP水平均降低，而ALB水平均升高（P＜0.05），且治疗组AST、ALT、TBIL、AFP水平均低于对照组，而ALB水平高于对照组（P＜0.05）。两组PT、APTT、TT水平均降低（P＜0.05），且治疗组PT、APTT、TT水平低于对照组（P＜0.05）。治疗组毒副反应发生率为16.67%，低于对照组的36.67%（P＜0.05）。结论 扶阳清毒法方药联合HAIC治疗中晚期肝癌患者的临床疗效确切，可有效减轻患者中医证候积分，降低患者肿瘤标志物水平，改善患者肝功能以及凝血功能，且安全性较高，值得临床推广应用。
Abstract:
Objective To investigate the effect of Fuyang Qingdu method combined with hepatic arterial infusion chemotherapy (HAIC) on tumor marker levels and toxicity in patients with advanced liver cancer. Methods A total of 60 patients with advanced liver cancer in Ganzhou Nankang District Hospital of Traditional Chinese Medicine from May 2024 to May 2025 were randomly divided into control and treatment groups, and each group had 30 patients. The control group was treated with HAIC, and the treatment group was treated with Fuyang Qingdu method on the basis of the control group. The clinical efficacy, TCM syndrome scores (rib pain, abdominal distension, anorexia, fatigue), liver function [total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB)], coagulation function [prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT)], alpha-fetoprotein (AFP) level and incidence of toxicity(nausea and vomiting, bone marrow suppression, liver function damage, renal function damage) were compared between the two groups. Results The total effective rate of the treatment group was 83.33%, which was higher than 66.67% of the control group (P<0.05). After treatment, the TCM syndrome scores of rib pain, abdominal distension, anorexia and fatigue in the two groups were decreased (P<0.05), and those in the treatment group were lower than those in the control group (P<0.05). The levels of AST, ALT, TBIL and AFP in the two groups decreased, while the level of ALB was increased (P<0.05). The levels of AST, ALT, TBIL and AFP in the treatment group were lower than those in the control group, while the level of ALB was higher than that in the control group (P<0.05). The levels of PT, APTT and TT in the two groups were decreased (P<0.05), and the levels of PT, APTT and TT in the treatment group were lower than those in the control group (P<0.05). The incidence oftoxicity in the treatment group was 16.67%, which was lower than 36.67% in the control group (P<0.05). Conclusion The clinical efficacy of Fuyang Qingdu method combined with HAIC in the treatment of patients with advanced liver cancer is definite, which can effectively reduce the TCM syndrome score of patients, reduce the level of tumor markers, improve the liver function and coagulation function of patients, and has high safety. It is worthy of clinical application.

参考文献/References:

[1]朱恒美,肖红梅,房树恒,等.肝动脉灌注化疗肝癌患者留置管路并发症预防管理最佳证据总结[J].介入放射学杂志,2025,34(4):425-429.[2]杨懿瑾,洪晗,陈彬,等.FOLFOX肝动脉灌注化疗联合仑伐替尼和PD-1抑制剂治疗中晚期原发性肝癌患者疗效研究[J].实用肝脏病杂志,2025,28(3):426-429.[3]杨文娟,吴美儿,张克勤,等.肝动脉灌注化疗对Ⅱ-Ⅲ期肝癌早期疗效的预测价值[J].介入放射学杂志,2025,34(5):493-495.[4]薛麟,肖翔.自体CIK细胞肝动脉灌注联合放化疗对原发性肝癌患者免疫功能及生活质量的影响[J].实用癌症杂志,2019,34(10):1625-1628.[5]陈敏捷,李国臣,赵平,等.基于扶阳学说中西医结合治疗慢加急性肝衰竭一例[J].环球中医药,2023,16(3):538-541.[6]郭旭彤,安继东,梅建强.扶阳调肝安神方联合西酞普兰治疗老年抑郁症疗效观察[J].现代中西医结合杂志,2021,30(6):603-606,611.[7]梁新梅,黎军宏,苟尧,等.从扶阳理论与内阳外阴本体结构探讨原发性肝癌的次第治疗[J].中华中医药杂志,2021,36(2):897-900.[8]孙婉卿,黄勇,韩涛,等.基于肝窦毛细血管化探讨清毒调肝方治疗肝纤维化的作用机制[J].新疆医科大学学报,2024,47(9):1293-1300.[9]张笛,陈月,杨佳璇,等.清毒汤保护肠屏障治疗慢加急性肝衰竭内毒素血症的机制研究[J].环球中医药,2024,17(11):2137-2142.[10]金双,高连印,赵梦培,等.清毒汤对实验性重症肝损伤大鼠Bax蛋白及Bcl-2蛋白表达的影响[J].首都医科大学学报,2018,39(1):79-83.[11]赵梦培,李爱红,崔颖,等.清毒汤对重症肝损伤大鼠肠上皮细胞自噬的影响[J].首都医科大学学报,2019,40(3):429-433.[12]李婷.疏肝清毒汤对肝郁型子宫颈癌化疗患者临床疗效、中医证候积分及凝血功能的影响[J].中医学报,2018,33(7):1182-1186.[13]吴秀颀,武博荣,裴艳涛,等.蛇芪清毒颗粒联合聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎疗效观察[J].现代中西医结合杂志,2020,29(18):2010-2012.[14]史昌河,赵文革,周永,等.大黄清毒汤灌肠改善肝硬化患者肠黏膜屏障功能的研究[J].中国中西医结合消化杂志,2018,26(1):99-101.[15]宋年,苏洁,陈露,等.基于扶阳理论探析扶阳罐对早期胃癌术后疲劳及炎症因子影响[J].中医药导报,2025,31(1):101-105.[16]刘德果,李姿蓉,胡金辉,等.由“阳化气,阴成形”理论探讨扶阳法在前列腺癌治疗中的应用[J].中华中医药杂志,2021,36(5):2775-2778.[17]毛德文,唐农,蓝艳梅,等.扶阳解毒化瘀散对慢性肝衰竭大鼠模型的干预研究[J].时珍国医国药,2019,30(5):1107-1110.[18]覃绿星,周晓玲,唐农,等.基于扶阳思想探讨慢加急性肝衰竭病机及治法[J].山东中医杂志,2019,38(11):1010-1013.[19]阮博文,周晓玲,覃凤传,等.应用“阳化气、阴成形”理论治疗非酒精性脂肪肝病的科学内涵[J].世界中医药,2024,19(22):3499-3507.[20]林杰,邓厚波,沈东,等.刘铁军教授运用扶阳益气法治疗肝癌发热临床经验[J].中西医结合肝病杂志,2018,28(3):185-187.

更新日期/Last Update: 1900-01-01